Ontology highlight
ABSTRACT:
SUBMITTER: Rimassa L
PROVIDER: S-EPMC6095177 | biostudies-literature | 2014 Apr
REPOSITORIES: biostudies-literature
Rimassa Lorenza L Porta Camillo C Borbath Ivan I Daniele Bruno B Finn Richard S RS Raoul Jean-Luc JL Schwartz Lawrence H LH He Aiwu Ruth AR Trojan Joerg J Peck-Radosavljevic Markus M Abbadessa Giovanni G Goldberg Terri T Santoro Armando A Bruix Jordi J
Hepatic oncology 20140129 2
There is no available effective systemic treatment for patients with advanced hepatocellular carcinoma (HCC) who are intolerant of sorafenib or who have disease that has progressed on sorafenib. In Phase I and II studies, tivantinib (ARQ 197), an oral inhibitor of MET, demonstrated promising antitumor activity in patients with HCC, both as monotherapy and in combination with sorafenib. A randomized Phase II trial in second-line HCC showed improved overall survival (hazard ratio: 0.38; p = 0.01) ...[more]